Have a feature idea you'd love to see implemented?
Let us know!
CRNX Crinetics Pharmaceuticals Inc
Price (delayed)
$58.74
Market cap
$4.7B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.76
Enterprise value
$4.45B
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate,
Highlights
The quick ratio has soared by 95% YoY but it has decreased by 9% QoQ
The revenue has dropped by 71% year-on-year and by 30% since the previous quarter
CRNX's gross profit has plunged by 71% YoY and by 30% from the previous quarter
Key stats
What are the main financial stats of CRNX
Market
Valuations
Earnings
Shares outstanding
80.04M
Market cap
$4.7B
Enterprise value
$4.45B
Price to earnings (P/E)
N/A
Price to book (P/B)
5.58
Price to sales (P/S)
3,350.85
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3,213.83
Revenue
$1.39M
EBIT
-$258.54M
EBITDA
-$254.26M
Free cash flow
-$185.05M
Per share
Balance sheet
Liquidity
EPS
-$3.76
Free cash flow per share
-$2.34
Book value per share
$10.53
Revenue per share
$0.02
TBVPS
$11.84
Total assets
$935.54M
Total liabilities
$104.77M
Debt
$53.32M
Equity
$830.76M
Working capital
$820.4M
Debt to equity
0.06
Current ratio
16.09
Quick ratio
15.89
Net debt/EBITDA
0.98
Margins
Efficiency
Dividend
EBITDA margin
-18,358.3%
Gross margin
100%
Net margin
-18,667.1%
Operating margin
-20,068.4%
Return on assets
-32.4%
Return on equity
-37%
Return on invested capital
-44.8%
Return on capital employed
-29.3%
Return on sales
-18,667.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CRNX stock price
How has the Crinetics Pharmaceuticals stock price performed over time
Intraday
0.58%
1 week
-0.31%
1 month
17.9%
1 year
97.64%
YTD
65.09%
QTD
14.95%
Financial performance
How have Crinetics Pharmaceuticals's revenue and profit performed over time
Revenue
$1.39M
Gross profit
$1.39M
Operating income
-$277.95M
Net income
-$258.54M
Gross margin
100%
Net margin
-18,667.1%
The revenue has dropped by 71% year-on-year and by 30% since the previous quarter
CRNX's gross profit has plunged by 71% YoY and by 30% from the previous quarter
The operating margin has plunged by 60% from the previous quarter
The net margin has dropped by 56% since the previous quarter
Growth
What is Crinetics Pharmaceuticals's growth rate over time
Valuation
What is Crinetics Pharmaceuticals stock price valuation
P/E
N/A
P/B
5.58
P/S
3,350.85
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3,213.83
The company's EPS fell by 11% YoY
CRNX's P/B is 59% above its 5-year quarterly average of 3.5 and 47% above its last 4 quarters average of 3.8
CRNX's equity is down by 5% since the previous quarter
The P/S is 161% above the last 4 quarters average of 1285.5
The revenue has dropped by 71% year-on-year and by 30% since the previous quarter
Efficiency
How efficient is Crinetics Pharmaceuticals business performance
The company's return on sales has shrunk by 56% QoQ
The ROA has increased by 41% YoY and by 12% from the previous quarter
The company's return on equity rose by 40% YoY and by 13% QoQ
The return on invested capital rose by 33% year-on-year and by 10% since the previous quarter
Dividends
What is CRNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CRNX.
Financial health
How did Crinetics Pharmaceuticals financials performed over time
The total liabilities has soared by 168% YoY
The quick ratio has soared by 95% YoY but it has decreased by 9% QoQ
The debt is 94% smaller than the equity
CRNX's equity is down by 5% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.